Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18919965 | LACTOBACILLUS ACIDOPHILUS GOLDGUT-LA100 HAVING FUNCTIONS OF LIPID LOWERING, BLOOD GLUCOSE LOWERING AND WEIGHT LOSS AND APPLICATION THEREOF | October 2024 | June 2025 | Allow | 8 | 2 | 0 | No | No |
| 18915656 | EVOLVED INTEGRASES AND METHODS OF USING THE SAME FOR GENOME EDITING | October 2024 | June 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18756561 | ANTI-FATIGUE LACTOBACILLUS COMPOSITION AND METHOD OF PROMOTING ANTI-FATIGUE PERFORMANCE AFTER AEROBIC EXERCISE OF SUBJECT IN NEED THEREOF BY USING THE SAME | June 2024 | October 2025 | Allow | 16 | 2 | 0 | No | No |
| 18722480 | SPINOSAD HIGH-YIELD STRAIN AND USE THEREOF | June 2024 | July 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18713690 | METHOD FOR INHIBITING BIOGENIC HYDROGEN SULFIDE IN OILFIELDS | May 2024 | July 2025 | Allow | 13 | 2 | 0 | No | No |
| 18588041 | CUPRIAVIDUS METALLIDURANS CML2, ITS PREPARATION, AND ITS BIOREMEDIATION METHOD FOR HEAVY METAL-CONTAMINATED ENVIRONMENT | February 2024 | September 2025 | Abandon | 18 | 2 | 0 | No | No |
| 18681293 | COMPOSITION FOR THE TREATMENT AND PREVENTION OF THE ESCA DISEASE | February 2024 | January 2026 | Allow | 24 | 3 | 0 | No | No |
| 18426195 | ESCHERICHIA COLI K-12 MG1655 BLBYZT6 AND APPLICATION THEREOF | January 2024 | March 2025 | Allow | 14 | 4 | 0 | Yes | No |
| 18450812 | Anti-Fatigue Lactobacillus Composition and Use Thereof | August 2023 | September 2024 | Abandon | 13 | 1 | 1 | No | No |
| 18001257 | SEMAGLUTIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | June 2023 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18339218 | CUTINASE HAVING IMPROVED ENZYMATIC ACTIVITY | June 2023 | December 2023 | Allow | 6 | 0 | 0 | No | No |
| 18333468 | COENZYME Q10 OILING AGENT, PREPARATION METHOD AND USE THEREOF | June 2023 | February 2026 | Abandon | 32 | 4 | 1 | No | No |
| 18324416 | CELLULOSE SACCHARIFICATION METHOD | May 2023 | October 2024 | Abandon | 16 | 2 | 0 | No | No |
| 18035430 | FOKI NUCLEASE DOMAIN MUTANT | May 2023 | February 2026 | Allow | 33 | 1 | 0 | No | No |
| 18135116 | METHOD OF PREPARING PROCOLLAGEN FROM FRESHWATER FISH | April 2023 | June 2025 | Abandon | 26 | 3 | 0 | No | No |
| 18031556 | ENGINEERED MICROORGANISMS EXPRESSING ACETOACETYL- COA REDUCTASE VARIANTS AND METHODS FOR INCREASING PROPORTION OF 3-HYDROXYHEXANOIC ACID IN PHA | April 2023 | December 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 18186488 | LAMBDA-CARRAGEENASE MUTANT OUC-CGLA-DPQQ AND APPLICATION THEREOF | March 2023 | January 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18172946 | GUIDE NUCLEIC ACID IDENTIFICATION AND METHODS OF USE | February 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18163866 | BACILLUS VELEZENSIS, FERMENTATION METHOD, FERMENTATION PRODUCT AND ITS APPLICATION | February 2023 | September 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17907864 | KLEBSIELLA PNEUMONIAE AND USE THEREOF | January 2023 | November 2025 | Allow | 39 | 2 | 0 | No | No |
| 18001243 | PROBIOTIC COMPOSITION FOR TREATMENT OF ORAL CANDIDA INFECTIONS | December 2022 | March 2026 | Allow | 39 | 2 | 0 | Yes | No |
| 17972906 | HYPOOSMOTIC STABILIZER FOR GENOMIC DNA OF GUT MICROBIOTA, AND PREPARATION METHOD AND USE THEREOF | October 2022 | May 2025 | Abandon | 31 | 4 | 0 | No | No |
| 17919762 | A chimeric endolysin polypeptide | October 2022 | October 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17904939 | LACTOBACILLUS HELVETICUS STRAIN AND COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES | August 2022 | July 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17801604 | BACTERIAL CULTURES FOR INCREASING VITAMIN B12 IN PLANTS | August 2022 | September 2025 | Allow | 37 | 2 | 0 | Yes | No |
| 17758676 | ANTI-TUMOR FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | July 2022 | December 2025 | Allow | 41 | 2 | 0 | No | No |
| 17781500 | SPLIT DEAMINASE BASE EDITORS | June 2022 | March 2026 | Abandon | 46 | 2 | 1 | No | No |
| 17780712 | A METHOD FOR THE TRANSFORMATION OF A LIQUID SUBSTRATE COMPRISING MICROORGANISMS, INTO A SUBSTANCE IN SOLID STATE AND RELATIVE SUBSTANCE | May 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17773533 | METHOD OF TREATING INFECTIONS BY BACTERIOLYTIC ENZYMES AND MANUFACTURE THEREOF | April 2022 | September 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17770591 | RECOMBINANT NEURAMINIDASE AND USES THEREOF | April 2022 | February 2026 | Allow | 46 | 2 | 1 | No | No |
| 17769596 | MICROBIAL COMPOSITIONS, STRAINS AND METHODS | April 2022 | March 2026 | Allow | 47 | 3 | 0 | No | No |
| 17762570 | MANNANASE FOR FORMULATIONS HAVING PH 5-12 | March 2022 | September 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17640187 | COMPOSITIONS AND METHODS FOR REDUCING CHROMATIN CONTENT OF BIOLOGICAL PREPARATIONS | March 2022 | November 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17753367 | ESCHERICHIA COLI-BASED RECOMBINANT STRAIN, CONSTRUCTION METHOD THEREFOR AND USE THEREOF | February 2022 | May 2025 | Allow | 39 | 2 | 0 | Yes | No |
| 17638340 | DETERGENT COMPOSITION | February 2022 | February 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17638118 | Recombinant Chorionic Gonadotropin, Procedure for Preparation, Pharmaceutical Compositions and Uses of the Same | February 2022 | April 2025 | Allow | 38 | 2 | 0 | No | No |
| 17633991 | OPTIMIZED CULTURE MEDIA FOR CLOSTRIDIA BACTERIA | February 2022 | September 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17633192 | METHOD FOR PREPARING PURE PLANT-BASED MICROBIAL CULTURE | February 2022 | August 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17586930 | PROTEINS FOR STABILIZATION OF BIOLOGICAL MATERIAL | January 2022 | May 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17625602 | PHARMACEUTICAL COMPOSITION CONTAINING LYSOZYME AND USE THEREOF | January 2022 | July 2025 | Abandon | 42 | 2 | 0 | Yes | No |
| 17568085 | PLANT PROTEIN-FURFURYL ALCOHOL WOOD ADHESIVE AND PREPARATION METHOD THEREOF | January 2022 | January 2025 | Abandon | 37 | 3 | 0 | Yes | No |
| 17565813 | CANDIDA UTILIS DOUBLE GENE CO-EXPRESSION STRAIN FOR HYDROLYZING PROTEIN COMPONENTS IN KITCHEN WASTE AND CONSTRUCTION METHOD THEREOF | December 2021 | December 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17562081 | Multifunctional lactobacillus capable of relieving pfoa toxic effects and application thereof | December 2021 | May 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17418653 | GENE EXPRESSION CASSETTE FOR EXPRESSING N-TERMINAL METHIONINE-TRUNCATED PROTEIN OF INTEREST AND METHOD FOR PRODUCING N-TERMINAL METHIONINE-TRUNCATED PROTEIN OF INTEREST BY USING SAME | December 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17620648 | BIFIDOBACTERIUM BIFIDUM BACTERIAL STRAIN, THE COMPOSITIONS THEREOF AND RELATED USES | December 2021 | October 2025 | Abandon | 46 | 4 | 0 | No | No |
| 17552103 | NAD(P) DEPOT FOR NAD(P)-DEPENDENT ENZYME-BASED SENSORS | December 2021 | June 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17596514 | COMPOSITION FOR AMELIORATION OF ANXIETY AND/OR STRESS | December 2021 | October 2025 | Allow | 46 | 3 | 0 | Yes | No |
| 17616842 | OLIVETOLIC ACID CYCLASE VARIANTS AND METHODS FOR THEIR USE | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17616547 | ASPARAGINASE-BASED CANCER THERAPY | December 2021 | March 2026 | Allow | 51 | 4 | 0 | No | No |
| 17615556 | PROBIOTICS TO INHIBIT ENTERIC PATHOGENS | November 2021 | August 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17595422 | ENZYMATIC PRODUCTION OF GLUCARIC ACID FROM GLUCURONIC ACID | November 2021 | February 2026 | Allow | 60 | 3 | 0 | Yes | No |
| 17610352 | COMPOSITION FOR PRODUCING GLUCOSYLATED STEVIOL GLYCOSIDE INCLUDING GLUCOSYLTRANSFERASE AND METHOD OF PRODUCING GLUCOSYLATED STEVIOL GLYCOSIDE USING THE SAME | November 2021 | May 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17608437 | KAURENOIC ACID 13-HYDROXYLASE (KAH) VARIANTS AND USES THEREOF | November 2021 | March 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17604630 | EXTREME THERMOPHILIC BACTERIA OF THE GENUS CALDICELLULOSIRUPTOR SUITABLE FOR THE CONVERSION OF CELLULOSIC AND STARCHY BIOMASS | October 2021 | March 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17603627 | METHOD AND PROCESS LINE FOR PRODUCING A DEWATERED GLUTEN-CONTAINING FRACTION | October 2021 | December 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17440303 | MODIFIED AGROBACTERIUM STRAINS AND USE THEREOF FOR PLANT TRANSFORMATION | September 2021 | May 2025 | Allow | 44 | 3 | 1 | Yes | No |
| 17432201 | RING NUCLEASE | August 2021 | May 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17429111 | PIC1 VARIANTS WITH IMPROVED SOLUBILITY AND METHODS OF USING THE SAME | August 2021 | September 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17426299 | RECOMBINANT DEAMIDATED GLIADIN POLYPEPTIDE ANTIGEN, RECOMBINANT ANTIGEN-EXPRESSING GENE, RECOMBINANT EXPRESSION VECTOR, AND PREPARATION METHOD AND APPLICATION THEREOF | July 2021 | February 2026 | Abandon | 54 | 2 | 0 | No | No |
| 17424761 | STRAIN FOR PRODUCING NATTOKINASE AND PRODUCTION METHOD THEREFOR | July 2021 | July 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17376613 | USE OF GALACTURONATE AND OR GALACTURONATE POLYMERS IN CONJUNCTION WITH CARBOHYDRATES TO CONTROL METABOLIC STATE OF ORGANISMS | July 2021 | November 2024 | Allow | 40 | 2 | 0 | Yes | Yes |
| 17418072 | E. COLI VARIANT STRAIN OR CORYNEBACTERIUM GLUTAMICUM VARIANT STRAIN PRODUCING L-AMINO ACIDS, AND METHOD FOR PRODUCING L-AMINO ACIDS USING SAME | June 2021 | November 2025 | Abandon | 52 | 3 | 0 | No | No |
| 17297850 | UOX-ALBUMIN CONJUGATE WITH CERTAIN NUMBERS OF ALBUMIN CONJUGATED THERETO, AND MANUFACTURING METHOD THEREOF | May 2021 | October 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17297931 | PURIFICATION METHOD FOR RECOMBINANT PROTEINS AND NANOPARTICLES | May 2021 | August 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17295847 | MICROBIAL CYTOMETRIC MOCK COMMUNITIES AND USE THEREOF AS STANDARD IN FLOW CYTOMETRY | May 2021 | July 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17323383 | HUMAN DNASE FOR LUNG DISEASE | May 2021 | January 2025 | Abandon | 44 | 2 | 0 | No | No |
| 13582372 | MASS SPECTROMETRIC MEASUREMENT OF B-LACTAMASE RESISTANCES | December 2012 | September 2020 | Abandon | 60 | 13 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MARTIN, RACHEL E.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 66.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner MARTIN, RACHEL E works in Art Unit 1657 and has examined 26 patent applications in our dataset. With an allowance rate of 42.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner MARTIN, RACHEL E's allowance rate of 42.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MARTIN, RACHEL E receive 2.08 office actions before reaching final disposition. This places the examiner in the 55% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MARTIN, RACHEL E is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +84.2% benefit to allowance rate for applications examined by MARTIN, RACHEL E. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.2% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.2% of cases where such amendments are filed. This entry rate is in the 28% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.